THE ASSOCIATED PRESS
December 22, 2013 - 9:35 am EST
NEW ORLEANS — Tulane University pathology professor Srikanta Dash has been awarded two National Institutes of Health grants totaling $2.6 million to study why some patients respond and other develop resistance to standard treatments for chronic hepatitis C.
The disease is the most common cause of end-stage liver disease.
Dash, director of Tulane's hepatitis research laboratory, received a $1.4 million, four-year grant from the National Institute of Allergy and Infectious Diseases to explore the mechanisms behind a gene that plays a critical role in whether a patient with hepatitis C responds to antiviral treatment.
The second award is a $1.2 million National Cancer Institute grant to study how chronic hepatitis C develop resistance to interferon therapies.